FISV DEADLINE REMINDER: Berger Montague Reminds Fiserv, Inc. (NASDAQ: FISV) (NYSE: FI) Investors of Important Class Action Lawsuit Deadline

National plaintiffs' law firm Berger Montague PCannounces that a class action lawsuit against Fiserv, Inc. (NASDAQ: FISV) (NYSE: FI) (“Fiserv” or the “Company”) has been filed on behalf of investors who purchased Fiserv shares during the period ofJuly 23, 2025 through October 29, 2025 (the “Class Period”). https://mma.prnewswire.com/media/232479/berger_montague.jpg Investor Deadline: Investors who purchased Fiservsecurities during […]

INSP INVESTOR ALERT: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut

Partner Reed Kathrein Urges Investors to Contact Firm Before January 5, 2026 Lead Plaintiff Deadline National investor rights law firm Hagens Berman alerts INSP investors to the pending securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP). The firm is urging INSP investors who suffered substantial losses to contact its attorneys before the

Northern Light Announces Leadership Transition as Part of LoneTree Capital Investment

Robert Trial Named Chief Executive Officer; Founder David Seuss to Continue as Principal Product Strategist. Company Also Announces Expansion of Senior Leadership Team. Northern Light, a leading provider of Competitive and Market Intelligence solutions for enterprises, today announced a planned leadership transition as part of its continued growth following LoneTree Capital's investment in the company.

KMX Shareholder Notice: CarMax (KMX) Securities Fraud Lawsuit Filed Over Alleged Concealed Demand Pull-Forward and Auto Finance Portfolio Risk – Hagens Berman

Partner Reed Kathrein Urges KMX Investors to Contact Firm Before January 2, 2026Lead Plaintiff Deadline National investor rights law firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against CarMax, Inc. (NYSE: KMX) — January 2, 2026 – is rapidly approaching. https://mma.prnewswire.com/media/2590203/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg The lawsuit alleges that CarMax and

JHX FINAL DEADLINE ALERT: Hagens Berman Scrutinizing Claims in Pending Class Action Suit Challenging James Hardie’s (JHX) Alleged Sales Practices

Partner Reed Kathrein Investigating Alleged Assurances of “Normal” Inventory Levels Against Later Revealed Destocking Trends National shareholder rights law firm Hagens Berman is issuing a reminder to investors in James Hardie Industries plc (NYSE: JHX) as the December 23, 2025, lead plaintiff deadline approaches in a pending securities class action against James Hardie and certain

Tiger Group Executive Offers Insights into the Drivers of Today’s Asset Valuation Environment

SFNet's 'In the Know' podcastcovers valuation shifts, tariff impacts, industry-specific pressures, and the expanding role of AI in appraisal analytics. Shifting tariffs, plunging consumer confidence and poor performance in once-thriving sectors like transportation and green energy have made timely and accurate appraisals increasingly critical in asset-based lending, advised the chief of Tiger Group's commercial and

F5, Inc. (FFIV) Faces Securities Class Action Amid Cybersecurity Incident, Questions About Disclosure Timing and Impact on Company’s Business – Hagens Berman

A securities class action lawsuit styled Smith v. F5, Inc., et al., No. 2:25-cv-02619 (W.D. Wash.) has been filed, seeking to represent investors in F5 (NASDAQ: FFIV)who purchased or otherwise acquired F5 securities between October 28, 2024 and October 27, 2025. https://mma.prnewswire.com/media/2590203/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg The lawsuit comes in the wake of F5's October 15, 2025 report that,

Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study

Aqualung Therapeutics, a clinical-stage immunotherapeutics company, announced today that the Food and Drug Administration (FDA) has cleared its Phase 2a study of ALT-100 mAb as an anti-inflammatory and anti-fibrotic therapy in human subjects with Progressive Pulmonary Fibrosis (PPF). This marks the company's second FDA-approved Investigational New Drug application (IND) following its 2022 clearance for acute

Appdome Breaks Records in G2 Winter 2026 Reports, Cementing Leadership in Mobile Fraud, Bot, and Security Categories

Appdome, the leader in protecting mobile businesses, today announced its best-ever performance in the G2 Winter 2026 Reports, achieving 37 badges across 75 reports, including multiple No. 1 rankings and new leadership positions in mobile fraud detection, mobile bot defense, no-code development, and runtime mobile protection. https://mma.prnewswire.com/media/772169/AppDome_Logo_9_27_23.jpg “Platforms, automation, and AI are driving Appdome's adoption,

Javvy Coffee Expands Its Protein Line with New Protein Creamer Flavors

Javvy Coffee, a leader in better-for-you coffee that's convenient, functional, and delicious, is expanding its Protein Coffee lineup with the launch of its newest innovation: Javvy Protein Creamer. With over one million happy customers, a viral social media presence, and retail launches at Target, Sprouts Farmers Market, and others; Javvy Coffee continues to redefine the

Scroll to Top